Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the "Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies, PDF files, or/and Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2012 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Papers

KRAS Mutation is Associated with Elevated Myeloblastin Activity in Human Lung Adenocarcinoma. T. WIEDL, S. COLLAUD, S. HILLINGER, S. ARNI, C. BURGESS, W. KROLL, P. SCHRAML, W. KROLL, P. SCHRAML, A. SOLTERMANN, H. MOCH, W. WEDER (Zurich, Switzerland; Cambridge, MA, USA)

Early detection of Ovarian Cancer in Pre-diagnosis Samples Using CA125 and MALDI MS Peaks. J.F. TIMMS et al (London; Reading, UK)

Decoding Differentially Regulated Epithelial and Stromal Pathways in Colorectal Cancer. M. ABBA, S. LAUFS, M. AGHAJANY, B. KORN, A. BENNER, H. ALLGAYER (Heidelberg, Germany)


Small Molecule Inhibition of Cytoskeletal Dynamics in Melanoma Tumors Results in Altered Transcriptional Expression Patterns of Key Genes Involved in Tumor Initiation and Progression. C. SPENCER, J. MONTALVO, S.R. MCLAUGHLIN, B.A. BRYAN (Worcester, MA, USA)

Gene Expression Profile Can Predict Pathological Response to Preoperative Chemoradiotherapy in Rectal Cancer. M. NISHIOKA, M. SHIMADA, N. KURITA, T. IWATA, S. MORIMOTO, K. YOSHIKAWA, J. HIGASHIJIMA, T. MIYATA (Tokushima, Japan)


Restoration of Senescence in Breast and Ovarian Cancer Cells Following the Transfer of the YAC Carrying SEN6A Gene Located at 6q16.3. N.S. RANE, A.K. SANDHU, V.S. ZHAWAR, G. KAUR, N.C. POPESCU, R.P. KANDPAL, M. JHANWAR-UNIYAL, R.S. ATTIWAL (Philadelphia, PA; Bethesda, MD; Pomona, CA; Valhalla, NY, USA)

Therapy- , Gender- and Race- specific microRNA Markers, Target Genes and Networks Related to Glioblastoma Recurrence and Survival. K.R. DELFINO, N.V.L. SERÃO, B.R. SOUTHEY, S.L. RODRIGUEZ-ZAS (Urbana, IL, USA)


The Cancer Biomarker Osteopontin: Combination with Other Markers (Review). G.F. WEBER (Cincinnati, OH, USA)

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma (Review). T. RIBARSKA, M. INGENWERTH, W. GOERING, W.A. SCHULZ (Düsseldorf, Germany)

TGF- β1 Interactome: Metastasis and Beyond (Review). M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAL, M.G. SMITH, A.J. TRACHITENBERG, W.P. KUO (Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer (Review). N. VALERI, C.M. CROCE, M. FABBRI (Columbus, OH, USA; Ferrara; Meldola, Italy)

The Continuing Search for Predisposing Colorectal Cancer Variants (Review). S. PICELLI, S. VON HOLST, P. WESSENDORF (Stockholm, Sweden)
Intraoperative Ultrasound: Improved Resection Rates in Breast-conserving Surgery. C. EICHLER, A. HÜBBEL, V. ZARGHOONI, A. THOMAS, O. GLUZ, M. STOFF-KHALILI, M. WARM (Cologne; Bonn; Berlin; Moenchengladbach, Germany) ................................................................. 1051

Coxsackie Adenovirus Receptor Expression in Carcinomas of the Head and Neck. T. WUNDER, U. SCHUMACHER, R.E. FRIEDRICH (Hamburg, Germany) .......................................................... 1057

Serum Antioxidant Capacity and Oxidative Injury to Pulmonary DNA in Never-smokers with Primary Lung Cancer. K. ITO, T. YANO, Y. MORODOMI, T. YOSHIDA, M. KOHNO, A. HARO, Y. SHIKADA, T. OKAMOTO, R. MARUYAMA, Y. MAEHARA (Fukuoka, Japan) .......................................................... 1063

Peritoneal Carcinomatosis from Solid Pseudopapillary Neoplasm (Frantz’s Tumour) of the Pancreas Treated with HIPEC. C. HONORE, D. GOERE, P. DARTIGUES, P. BURTIN, F. DUMONT, D. ELIAS (Villejuif, France) .......................................................... 1069

Cystic Teratoma of the Pancreas. J. SCHEELE, T.F.E. BARTH, M. WITTAU, M. JUCHEMS, D. HENNEBRUNS, M. KORNMANN (Ulm, Germany) .......................................................... 1075

WTI Peptide Therapy for a Patient with Chemotherapy-resistant Salivary Gland Cancer. T. SHIRAKATA, Y. OKA, S. NISHIDA, N. HOSEN, A. TSUBOI, Y. OJI, A. MURAO, H. TANAKA, S.-I. NAKATSUKA, H. INOHARA, H. SUGIYAMA (Ehime; Osaka; Tochigi; Hyogo, Japan) .......................................................... 1081

Repeat Transrectal Ultrasound Biopsies with Additional Targeted Cores According to Results of Functional Prostate MRI Detects High-risk Prostate Cancer in Patients with Previous Negative Biopsy and Increased PSA – A Pilot Study. C. ARSOV, M. QUENTIN, R. RABENALT, G. ANTOCH, P. ALBERS, D. BLONDIN (Düsseldorf, Germany) .......................................................... 1087


Twice-daily Dosing of Temozolomide in Combination with Fotemustine for the Treatment of Patients with Refractory Glioblastoma. M. SANTONI, A. PACCAPELO, L. BURATTINI, A. ONOFRI, S. CASCINU (Ancona, Italy) .......................................................... 1099

Interstitial Lung Disease Associated with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer. A. TAMIYA, T. NAITO, S. MIURA, S. MORII, A. TSUYA, Y. NAKAMURA, K. KAIRA, H. MURAKAMI, T. TAKAHASHI, N. YAMAMOTO, M. ENDO (Shizuoka, Japan) .......................................................... 1103


No Consistent Relationship of Glioblastoma Incidence and Cytomegalovirus Seropositivity in Whites, Blacks, and Hispanics. S. LEHRER, S. GREEN, L. RAMANATHAN, K. ROSENZWEIG, V. LABOMBARDI (New York, NY, USA) .......................................................... 1113

Errata .......................................................... 1117

* Reviews (pages 873, 947, 989, 997, 1005)
Integrated Genomic Characterization of the Kallikrein Gene Locus in Cancer. A.H. GIRGIS, A. BUI, N.M. WHITE, G.M. YOUSEF (Toronto, ON, Canada) ............................................................. 957

Small Cell Osteosarcoma Successfully Treated by High-dose Ifosfamide and Methotrexate, Combined with Carboplatin and Pirarubicin. H. FUTANI, S. FUKUNAGA, Y. TSUKAMOTO, N. TERADA, J. ONO, N. OKAMOTO, Y. OTSUKA, T. TANIZAWA, M. TOMATSURI, S. YOSHIYA (Kobe, Hyogo, Japan) .... 957

Phase I Study of Sunitinib plus Modified FOLFOX6 in Japanese Patients with Treatment-naive Colorectal Cancer. T. YOSHINO, K. YAMAZAKI, T. HAMAGUCHI, Y. SHIMADA, K. KATO, H. YASUI, N. BOKU, M.J. LECHUGA, T. HIROHASHI, A. SHIBATA, SA. HASHIGAKI, Y. LI, A. OHTSU (Kashiwa, Chiba; Shizuoka; Tokyo, Japan; Milan, Italy) .... 973

Vitamin D and Pancreatic Cancer Risk – No U-Shaped Curve. L.L. BAGGERLY, C.F. GARLAND (Encinitas; San Diego, CA, USA) ......................................................... 981

Simultaneous Multianalyte Immunoassay Measurement of Five Serum Tumor Markers in the Detection of Colorectal Cancer. FRANCO LUMACHI, FILIPPO MARINO, ROCCO ORLANDO, GIORDANO B. CHIARA, STEFANO M.M. BASSO (Padova; Pordenone, Italy) ........................................ 985

* Review: Modulation of Systemic and Intestinal Immune Response by Interleukin-2 Therapy in Gastrointestinal Surgical Oncology. Personal Experience in the Context of Current Knowledge and Future Perspectives. L. NESPOLI, F. UGGERI, F. ROMANO, A. NESPOLI, F. BRIVO, L. FUMAGALLI, M. SARGENTI, F. UGGERI, L. GIANOTTI (Monza; Cinisello Balsamo; Lecco; Milan, Italy) ......................... 989

* Review: Immunotherapy Approaches Targeting Regulatory T-Cells. H. ONISHI, T. MORISAKI, M. KATANO (Fukuoka, Japan) ......................................................... 997


Soluble Human Leukocyte Antigen-G Expression in Patients with Ductal and Lobular Breast Malignancy. X. PROVATOPOULOU, E. KALOGERA, A. SAGKRIOTIS, F. ZAGOURI, A. NONNI, G.C. ZOGRAFOS, A. GOUNARIS (Athens, Greece) ......................................................... 1021

Phase II Study of Panobinostat and Bortezomib in Patients with Pancreatic Cancer Progressing on Gemcitabine-based Therapy. H. WANG, Q. CAO, A.Z. DUDEK (Minneapolis, MN, USA) ......................................................... 1027

Sentinel Lymphadenectomy Compared to Extended Lymphadenectomy in Men with Prostate Cancer Undergoing Prostatectomy. A. PONHOLZER, M. LAMCHE, M. KLITSCH, N. KRAISCHITS, M. HIESS, M. SCHENNER, C. BROSSNER, P. SCHRAMEK (Vienna, Austria) ......................................................... 1033


Combined Oral Topotecan plus Carboplatin in Relapsed or Advanced Cervical Cancer: A GINECO Phase I-II Trial. J.E. KURTZ, G. FREYER, F. JOLY, L. GLADIEFF, M.C. KAMINSKI, M. FABBRO, A. FLOQUET, A.C. HARDY-BESSARD, N. RABAN, I. RAY-COQUARD, E. PUIADE-LAURaine (Strasbourg; Pierre-Bénite; Caen; Toulouse; Vandœuvre-lès-Nancy; Montpellier; Bordeaux; Saint Brieuc; Poitiers; Lyon; Paris, France) ...... 1045

Contents continued on the preceding page
The Expression of CD146 Predicts a Poor Overall Survival in Patients with Adenocarcinoma of the Lung. S. OKA, H. URAMOTO, Y. CHIKAISHI, F. TANAKA (Kitakyushu, Japan) .................................................. 861

SN-38 Overcomes Chemoresistance of Colorectal Cancer Cells Induced by Hypoxia, through HIF1alpha. K. MURONO, N.H. TSUNO, K. KAWAI, K. SASAKI, K. HONGO, M. KANEKO, M. HIYOSHI, N. TADA, T. NIREI, E. SUNAMI, K. TAKAHASHI, J. KITAYAMA (Tokyo, Japan) .................................................. 865

* Review: The Role of Canonical WNT Signaling Pathway in Oral Carcinogenesis: A Comprehensive Review. J. NOGUTI, C.F.G. DE MOURA, T. AYAKO HOSSAKA, M. FRANCO, C.T. FUJIYAMA OSHIMA, R.A. DEDIVITIS, D.A. RIBEIRO (São Paulo; Santos, SP, Brazil) .................................................. 873

Decreased Levels of Histone H3K9me1 Indicate Poor Prognosis in Patients with Renal Cell Carcinoma. S. ROGENHOFER, P. KAHL, S. HOLZAPFEL, A. VON RUECKER, S.C. MUELLER, J. ELLINGER (Bonn; Cologne, Germany) .................................................. 879


Expression of Cathepsin-D in Primary Breast Cancer and Corresponding Local Recurrence or Metastasis: An Immunohistochemical Study. D. DIAN, T. VREKOUSIS, N. SHABANI, I. MYLONAS, C. KUHN, C. SCHINDLBECK, I. NAVROZOGLOU, K. FRIESE, A. MAKRIGIANNAKIS, U. JESCHKE (Munich, Germany; Ioannina; Heraklion, Greece) .................................................. 901


Impact of Temperature on Cell Death in a Cell-culture Model of Hepatocellular Carcinoma. B. LEBER, U. MAYRHAUSER, B. LEOPOLD, S. KOESTENBAUER, K. TSCHIESSNIGG, V. STIEGLER (Graz, Austria) .................................................. 915


Clinical Studies

Cisplatin with Capecitabine: Tolerance and Activity in a Phase I/II Study Preferentially Enrolling Patients with Gastric Cancer. J. WU, TH. RYAN, B. LEVINSON, E. NEWMAN, H.S. HOCHSTER, F. MUGGIA (New York, NY; New Haven, CT USA) .................................................. 939

* Review: Is Surgical Trauma Prometastatic? F.J. LEJEUNE (Lausanne, Switzerland) .................................................. 947

Biweekly Docetaxel Is Better Tolerated than Conventional Three-weekly Dosing for Advanced Hormone-refractory Prostate Cancer. P. HERVONEN, H. JOENSUU, T. JOENSUU, G. CLAES, M. RAY, H. ULRIKA, N. PAUL, L. TIINA, H. AKSEL, Z. IGOR, H. MIRJA, N. STEN, L. MARJAANA, L. ILARI, K.-L. PIRKKO-LIISA (Tampere; Helsinki; Lahti; Oulu; Turku, Finland; Karlstad; Stockholm, Sweden; Dublin, Ireland) .................................................. 953

Contents continued on the preceding page
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receptor Affinity and Preclinical Biodistribution of Radiolabeled Somatostatin Analogs</td>
<td>M. LAZNICEK, A. LAZNICKOVA, H.R. MAECKE (Hradec Kralove, Czech Republic; Freiburg, Germany)</td>
<td>...............................................</td>
<td>761</td>
</tr>
<tr>
<td>Tissue Microarray Technique in Evaluation of Proliferative Activity in Invasive Ductal Breast Cancer</td>
<td>C. KOBIERZYCKI, B. PULA, A. WOJNAR, M. PODHORSKA-OKOLOW, P. DZIEGIEL (Wrocław; Poznan, Poland)</td>
<td>...............................................</td>
<td>773</td>
</tr>
<tr>
<td>Antitumor Activity of an Interleukin-2 Monoclonal Antibody in a Murine Osteosarcoma Transplantation Model</td>
<td>K. KOHYAMA, H. SUGIURA, E. KOZAWA, J. WASA, K. YAMADA, A. NISHIOKA, Y. KAMEI, O. TAGUCHI (Nagoya, Japan)</td>
<td>...............................................</td>
<td>779</td>
</tr>
<tr>
<td>Cetuximab Sensitivity Associated with Oxaliplatin Resistance in Colorectal Cancer</td>
<td>L. EKBLAD, A. JOHNSON (Lund, Sweden) ...............................................</td>
<td>...............................................</td>
<td>783</td>
</tr>
<tr>
<td>Methylation of TFPI2 No Longer Detected in the Serum DNA of Colorectal Cancer Patients after Curative Surgery</td>
<td>K. HIBI, T. GOTO, A. SHIRAHATA, M. SAITO, G. KIGAWA, H. NEMOTO, Y. SANADA (Yokohama, Japan)</td>
<td>...............................................</td>
<td>787</td>
</tr>
<tr>
<td>Detection of Vimentin Methylation in the Serum of Patients with Gastric Cancer</td>
<td>A. SHIRAHATA, K. SAKURABA, Y. KITAMURA, Y. KOKOMIZO, T. GOTO, M. SAITO, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (Yokohama, Japan)</td>
<td>...............................................</td>
<td>791</td>
</tr>
<tr>
<td>Antiproliferative and Antitumor Effects of Azacitidine Against the Human Myelodysplastic Syndrome Cell Line SKM-1</td>
<td>S. KIMURA, K. KURAMOTO, J. HOMAN, H. NARUOKA, T. EGO, M. NOGAWA, S. SUGAHARA, H. NAITO (Kyoto, Japan)</td>
<td>...............................................</td>
<td>795</td>
</tr>
<tr>
<td>Transforming Growth Factor Beta Receptor I Inhibitor Sensitizes Drug-resistant Pancreatic Cancer Cells to Gemcitabine</td>
<td>Y.J. KIM, J.S. HWANG, Y.B. HONG, I. BAE, Y.-S. SEONG (Cheonan; Daegu, South Korea; Washington, DC, USA)</td>
<td>...............................................</td>
<td>799</td>
</tr>
<tr>
<td>Fucoxanthin Induces GADD45A Expression and G1 Arrest with SAPK/JNK Activation in LNCap Human Prostate Cancer Cells</td>
<td>Y. SATOMI (Suzuka, Mie, Japan) ...............................................</td>
<td>...............................................</td>
<td>807</td>
</tr>
<tr>
<td>Different Radioactivity Uptake between Somatostatin Analogues Labelled with $^{111}$In and $^{90/88}$Y in Rat Kidney</td>
<td>M. LAZNICKOVA, A. LAZNICKOVA (Hradec Kralove, Czech Republic)</td>
<td>...............................................</td>
<td>815</td>
</tr>
<tr>
<td>Enhanced Renal Clearance of Vancomycin in Rats with Carcinogen-Induced Osteosarcoma</td>
<td>I. SHIMADA, C. IWATA, S. TAGA, H. TERAMACHI, M. NOMURA, K.-I. MIYAMOTO, H. TSUCIYA, T. WADA, K. KIMURA, R. MATSUSHITA (Kanazawa; Gifu, Japan)</td>
<td>...............................................</td>
<td>823</td>
</tr>
<tr>
<td>Farnesyltransferase Inhibitors: Molecular Evidence of Therapeutic Efficacy in Acute Lymphoblastic Leukemia Through Cyclin D1 Inhibition</td>
<td>C.B. COSTA, J. CASALTALOPEZ, C. ANDRADE, D. MOREIRA, A. OLIVEIRA, A.C. GONÇALVES, V. ALVES, T. SILVA, M. DOURADO, J.M. NASCIMENTO-COSTA, A.B. SARMENTO-RIBEIRO (Coimbra; Lisbon; Portugal)</td>
<td>...............................................</td>
<td>831</td>
</tr>
<tr>
<td>Proteomic Analysis of Exosome-like Vesicles Derived from Breast Cancer Cells</td>
<td>G. PALAZZOLO, N.N. ALBANESE, G. DI CARA, D. GYGAX, M.L. VITTORELLI, I. PUCCI-MINAFRA (Zurich; Muttenz, Switzerland; Palermo, Italy)</td>
<td>...............................................</td>
<td>847</td>
</tr>
</tbody>
</table>